[Laboratory and clinical studies on cefotaxime in obstetrics and gynecology (author's transl)].
The following results have been obtained in our basic and clinical studies to examine a new cephalosporin derivative, cefotaxime (CTX). For basic study purpose, we injected 1 g of CTX to 6 patients who had received simple total hysterectomy and measured its level in elbow vein, uterine artery, corpus uteri, cervix uteri, endometrium, oviduct and ovary. Any definitive conclusion should not be drawn from these results, since they have too big variation. However, slightly higher levels were achieved cervix uteri and oviduct than in other organs in a same patient. For clinical evaluation, we tried this drug to 12 cases of female genital infections and 91.7% response rate was obtained. Our studied population includes 8 cases of adnexitis, 2 with pelvioperitonitis, 1 with panperitonitis, and 1 patient with BARTHOLIN abscess. Organisms were detected only in 3 cases, including S. aureus in one patient, Micrococcus sp. in one, and mixture of Klebsiella sp. and B. fragilis in 1. Puncture of DOUGLAS pouch was performed in 3 cases after the completion of therapy and all had negative results. No side effect was observed, and no significant difference was noted between pre- and post-therapy examinations of peripheral blood, hepatic function and renal function.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy; D002439:Cefotaxime / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005836:Genitalia, Female / Q000378:metabolism; D006801:Humans; D008875:Middle Aged
D002439:Cefotaxime